| Literature DB >> 7678046 |
Abstract
Iron-deficient anaemic infants perform worse in tests of mental and motor development than do iron-sufficient infants of a comparable age. A randomised, double-blind trial was done to monitor the effects of iron supplementation on performance in the Bayley scales of mental and motor development among 12-18-month-old infants in Indonesia. Iron-deficient anaemic infants (n = 50) were assigned randomly to receive dietary ferrous sulphate or placebo for 4 month. Similar treatment randomisation was done among nonanaemic iron-deficient (n = 29) and iron-sufficient (n = 47) infants. Before intervention, the mean mental and motor scores of the iron-deficient anaemic infants were significantly (p < 0.01) lower than those of the nonanaemic iron-deficient and iron-sufficient classes. After intervention, developmental delays were reversed among iron-deficient anaemic infants who had received iron but they remained the same among placebo-treated iron-deficient anaemic infants. Neither ferrous sulphate nor placebo had significant effects on the scores of the other two iron-status classes. The poor performance of 12-18-month-old iron-deficient anaemic infants in the Bayley scales of mental and motor development can be improved to the level of performance of iron-sufficient infants by treatment with ferrous sulphate.Entities:
Keywords: Age Factors; Asia; Biology; Child Development; Clinical Research; Clinical Trials; Delivery Of Health Care; Demographic Factors; Developing Countries; Double-blind Studies; Food Supplementation; Health; Health Services; Hemic System; Hemoglobin Level; Indonesia; Infant; Ingredients And Chemicals; Inorganic Chemicals; Iron--administraction and dosage; Metals; Nutrition Programs; Physiology; Population; Population Characteristics; Primary Health Care; Research Methodology; Serum Iron Level--analysis; Southeastern Asia; Studies; Youth
Mesh:
Substances:
Year: 1993 PMID: 7678046 DOI: 10.1016/0140-6736(93)92477-b
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321